Market News How it works Learn FAQ
| TGL 0.2897 30.79% | SRTM 0.6164 43.25% | NU 11.845 -21.87% | GCDT 0.1604 -8.92% | EWZ 31.98 -24.91% | NWGL 0.0808 -1.46% | SHFS 0.1254 -5.29% | RBNE 0.183 -3.68% | CLRO 4.2705 31.40% | SPRC 1.635 50.00% | SOXL 87.29 4.46% | BBD 2.9088 -28.53% | VBIO 0.785 -16.49% | RENT 2.85 23.91% | ITUB 7.63 -21.10% | PBR 21.675 -17.14% | SOXS 50.2 -4.31% | TSLL 10.68 9.43% | SPCX 147.12 -0.25% | XP 14.42 -52.58% | XXII 0.1032 -47.80% | GPUS 0.1583 -6.28% | WFF 0.0741 -7.38% | KORU 10.59 0.09% | CRWV 52.0841 -3.97% | IREN 24.13 -3.11% | STNE 7.83 -31.79% | SQQQ 39.02 -1.66% | PRSO 0.35 -7.51% | NOK 8.44 3.69% | INTR 4.751 -33.92% | MYND 0.2219 -7.54% | TQQQ 67.37 1.63% | INTC 88.11 1.32% | VALE 12.27 -1.05% | NVDA 214.88 1.86% | TSLA 389.99 4.77% | VZ 43.45 -2.71% | IBIT 44.9769 -2.14% | WORX 2.2101 0.92% | YMAT 2.25 9.76% | AZTR 0.9102 1,173.01% | JBLU 2.4312 -7.38% | STLA 4.105 1.11% | WULF 11.36 0.35% | T 21.075 0.69% | IRE 2.9 -6.15% | PAGS 8.6 -24.83% | META 631.35 -1.75% | NBIS 151.07 -4.83%
BIBiocept, Inc. logo

Biocept, Inc. (BIOC)

NASDAQ Capital Market · Currency in USD
$0.43 ▲ +0.00 (+0.00%)
As of Jan 16, 4:00 PM ET. Market open.

Summary

Previous Close
$0.43
Open
$0.49
Day's Range
$0.43 – $0.49
52 Week Range
$0.43 – $0.49
Volume
572,521
Avg. Volume
2,163,433
Market Cap
$450.79K
Beta (5Y Monthly)
0.60
PE Ratio (TTM)
--
EPS (TTM)
-$56.78
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Biocept, Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
50
CEO
Darrell Taylor

Biocept, Inc. is a company specializing in molecular diagnostics for cancer, primarily focused on developing and commercializing advanced diagnostic assays based on proprietary technology. These tests analyze circulating tumor cells (CTCs) and cell-free tumor DNA and RNA (ctDNA/ctRNA), primarily using standard blood samples. These assays furnish crucial insights to healthcare professionals, enabling them to identify specific genetic changes (oncogenic alterations) that qualify certain cancer patients for targeted therapies.

Earnings

DateEst.Actual
Nov 20, 2023–-$9.91
Aug 14, 2023–-$3.50
Apr 17, 2023–-$32.73
Mar 29, 2023-$0.22-$32.57Miss
Nov 21, 2022-$4.80-$9.91Miss
Nov 10, 2022-$0.16-$9.31Miss

Analyst view

Rating: Hold
Buy 33% · Hold 67% · Sell 0%

Get free alerts on BIOC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.